Montreal Cognitive Assessment (Moca) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Montreal Cognitive Assessment (MoCA) is a widely used cognitive screening instrument designed to detect mild cognitive impairment (MCI). Developed in 2005 by Ziad Nasreddine and colleagues at the Memory Clinic of the McGill University Health Centre in Montreal, Canada, the MoCA has become one of the most frequently used cognitive screening tools in clinical and research settings[1].
The MoCA is a brief, 10-minute test that assesses multiple cognitive domains. It was specifically designed to be more sensitive than the Mini-Mental State Examination (MMSE) for detecting milder forms of cognitive impairment, particularly in the early stages of neurodegenerative diseases[2]. The test has been validated in hundreds of peer-reviewed studies and is available in over 50 languages and dialects[3].
The MoCA assesses six major cognitive domains1:
The test includes delayed recall of a five-word list, evaluating verbal memory function. This component is particularly sensitive to early memory deficits seen in Alzheimer's Disease2 and other dementias[1:1].
Participants are asked to copy a cube and draw a clock face with a specific time. These tasks assess visuoconstructional skills and spatial planning abilities that are often affected in Frontotemporal Dementia and Posterior Cortical Atrophy[2:1].
Executive function is assessed through a trail-making task (alternating between numbers and letters), phonemic fluency, and the clock-drawing task. These functions are particularly vulnerable in Parkinson's Disease, Huntington's Disease, and vascular cognitive impairment[3:1].
Simple attention is tested through a digit span task (forward and backward), while sustained attention is assessed via a continuous subtraction task. Working memory is evaluated through the digit span backward component[1:2].
Language assessment includes object naming, sentence repetition, and phonemic fluency (generating words beginning with a specific letter). Language deficits are prominent in Primary Progressive Aphasia and Alzheimer's Disease[2:2].
Participants are asked to state the current date, day of week, and location (city, hospital/clinic). Disorientation is a hallmark of advanced dementia but can appear early in certain conditions[1:3].
The MoCA is scored out of 30 points, with different cognitive domains contributing varying numbers of points:
| Domain | Maximum Points |
|---|---|
| Visuospatial/Executive | 5 |
| Naming | 3 |
| Attention | 6 |
| Language | 3 |
| Abstraction | 2 |
| Delayed Recall | 5 |
| Orientation | 6 |
A score of 26 or above is generally considered within the normal range, though the cutoff may vary based on education level and demographic factors[3:2]. However, some studies suggest that age and education-adjusted cutoffs may be more appropriate for specific populations[4].
The MoCA is used to detect and monitor cognitive impairment in numerous neurodegenerative conditions2:
The MoCA is highly sensitive (90%) for detecting mild cognitive impairment due to Alzheimer's Disease, significantly outperforming the MMSE (18% sensitivity) in this regard[3:3]. It is commonly used in memory clinics and research trials for early detection.
In Parkinson's Disease, the MoCA is used to detect Parkinson's Disease Mild Cognitive Impairment (PD-MCI), which affects up to 50% of PD patients. Specific subtests, particularly executive function and attention tasks, are particularly sensitive to PD-related cognitive changes[2:3].
The MoCA can help distinguish Lewy Body Dementia from Alzheimer's Disease, as patients with LBD often show particular deficits in attention and executive functions. Fluctuations in cognition, a core feature of LBD, can also be assessed through repeated administrations[3:4].
Patients with FTD often show characteristic patterns of impairment on the MoCA, with particular deficits in executive function and language tasks. The test helps differentiate FTD from Alzheimer's Disease, which typically shows more prominent memory impairment[2:4].
Cognitive decline is a core feature of Huntington's Disease, and the MoCA is used to track disease progression. Executive dysfunction and attention deficits are typically the earliest cognitive changes detected[3:5].
The MoCA is sensitive to the cognitive deficits associated with cerebrovascular disease, including multi-infarct dementia and subcortical Vascular Dementia. Executive function and attention tasks are particularly affected in VCI[4:1].
Cognitive impairment, including frontotemporal dysfunction, occurs in up to 50% of ALS patients. The MoCA provides a brief screening tool to detect these deficits, though more comprehensive neuropsychological testing is often warranted[3:6].
The MoCA offers several advantages over the older MMSE:
Despite its widespread use, the MoCA has limitations:
Multiple versions of the MoCA have been developed to address various clinical needs[3:8]:
The study of Montreal Cognitive Assessment (Moca) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Dynamic functional connectivity measures are more reliable than stationary connectivity measures in attention networks
Dorsal attention network (DAN) Factor 3 (anterior DAN) obtained at rest significantly predicts alerting effect on Attention Network Test in both sessions (p=0.001 and p=0.037)
Fronto-parietal task control network (FPTC) Factor 3 predicts orienting effect at Session 1 (p=0.010)
The relationship between DAN Factor 3 and alerting effect was present during both rest and task conditions
Changes in dynamic connectivity factor scores between sessions correlated with changes in accuracy in Incongruent Flanker trials
Higher dynamic connectivity (factor scores) was associated with larger alerting and orienting effects, possibly reflecting more effortful processing or rigidity in resource reallocation
No significant group differences in ICA-defined resting networks between PD and controls, suggesting subtle differences in early-stage PD
Dynamic connectivity factor structures are stable across rest and task states (Procrustes congruence 0.89-0.93 for DAN)
Individual differences in dynamic connectivity are reliable across scanner sessions but not invariant, and changes reflect behavioral changes
PD participants showed slowed response latencies across all conditions. PD participants had significantly larger alerting effect (No Cue - Center Cue) compared to controls (PD: 47ms vs Controls: 28ms, p=0.025). No significant differences in orienting or executive effects between groups.
Model System: Human participants: 25 Parkinson disease (PD) patients and 21 healthy controls (ages 41-86)
Statistical Significance: p = 0.025 for alerting effect difference between groups
Identified dorsal attention network (DAN), salience network, and default mode network (DMN). No significant group differences found between PD and controls in these networks.
Model System: Human participants: 25 PD patients and 21 controls undergoing resting-state fMRI
Statistical Significance: No significant group differences (p > 0.05 after correction)
Extracted 4 factors for each network (DAN, FPTC, DMN). Factor structures were qualitatively similar to previous aging sample but explained less variance in this sample. Reliability of factor scores was higher than reliability of individual pairwise correlations.
Model System: Human participants: 25 PD and 21 controls during resting-state fMRI scans
Statistical Significance: DAN factor reliability 0.56-0.64, FPTC 0.35-0.69, DMN 0.57-0.78 (all p < 0.01 except FPTC Factor 4 p=0.01)
Dynamic connectivity measures are more reliable than stationary connectivity measures. Median reliability of factor scores higher than median reliability of pairwise correlations for DAN (p=0.020) and DMN (p=0.036). FPTC showed marginally significant difference (p=0.082).
Model System: Same 46 participants in resting-state fMRI
Statistical Significance: DAN: p=0.020, DMN: p=0.036, FPTC: p=0.082
DAN Factor 3 (anterior DAN) significantly predicted alerting effect magnitude at both sessions (Session 1: p=0.001, R2=0.21; Session 2: p=0.037, R2=0.09). Effect remained significant after controlling for age. Group-by-factor interaction significant at Session 1 (p=0.002) but not Session 2.
Model System: 46 participants (25 PD, 21 controls) from resting-state scans to ANT performance
Statistical Significance: Session 1: t(44)=3.46, p=0.001; Session 2: t(44)=2.15, p=0.037; Group x Factor interaction Session 1: p=0.002
FPTC Factor 3 predicted orienting effect at Session 1 (p=0.010) but not Session 2 (p=0.116). No significant group or group-by-factor interaction.
Model System: 46 participants from resting-state scans to ANT orienting effect
Statistical Significance: Session 1: t(44)=2.70, p=0.010; Session 2: t(44)=1.6, p=0.116
DAN factor structure during task highly congruent with rest (Procrustes correlation 0.93 Session 1, 0.89 Session 2, p=0.001). DAN Factor 3 during tasks predicted alerting effect (Session 1: p=0.023, R2=0.11; Session 2: p=0.107). During tasks, DAN Factor 3 also negatively predicted orienting effect at Session 2 (p=0.013).
Model System: 46 participants during ANT task fMRI runs
Statistical Significance: DAN Factor 3: Session 1 p=0.023, Session 2 p=0.107; Orienting: Session 2 p=0.013
Increase in DAN Factor 3 between sessions correlated with improvement in accuracy in Incongruent Flanker condition (r=0.37, p=0.011). Increase in FPTC Factor 3 correlated with improvement in Incongruent (r=0.39, p=0.007) and Center Cue conditions (r=0.32, p=0.027).
Model System: Longitudinal: Session 1 to Session 2 change in same 46 participants
Statistical Significance: DAN Factor 3: r(44)=0.37, p=0.011; FPTC Factor 3 Incongruent: r(44)=0.39, p=0.007; FPTC Factor 3 Center Cue: r(44)=0.32, p=0.027
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment[1]. J Am Geriatr Soc. 2005;53(4):695-699. DOI:10.1111/j.1532-5415.2005.53273.x ↩︎ ↩︎ ↩︎ ↩︎
Memória CM, Yassuda MS, Nakano EY, Forlenza OV. Brief screening tools for mild cognitive impairment: a systematic review on psychometric properties. Dement Geriatr Cogn Disord. 2013;35(1-2):1-14. DOI:10.1159/000345435 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
MoCA Cognition. Official MoCA Test Website. https://mocacognition.com/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Carson N, Leach L, Murphy KJ. A re-examination of Montreal Cognitive Assessment (MoCA) cutoff scores. J Geriatr Psychiatry Neurol. 2018;31(1):3-8. DOI:10.1177/0891988717753601 ↩︎ ↩︎